These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 1849042)

  • 61. Rapamycin reverses the senescent phenotype and improves immunoregulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway.
    Gu Z; Tan W; Ji J; Feng G; Meng Y; Da Z; Guo G; Xia Y; Zhu X; Shi G; Cheng C
    Aging (Albany NY); 2016 May; 8(5):1102-14. PubMed ID: 27048648
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer.
    Faller BA; Pandit TN
    Clin Med Insights Oncol; 2011; 5():131-44. PubMed ID: 21695100
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer.
    Curran MP; Plosker GL
    Drugs Aging; 2002; 19(9):695-721. PubMed ID: 12381238
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials.
    Nguyen L; Tranchand B; Puozzo C; Variol P
    Br J Clin Pharmacol; 2002 May; 53(5):459-68. PubMed ID: 11994051
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP).
    Linkesch W; Weger M; Eder I; Auner HW; Pernegg C; Kraule C; Czejka MJ
    Eur J Drug Metab Pharmacokinet; 2001; 26(3):179-84. PubMed ID: 11695718
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Vinorelbine--a clinical review.
    Gregory RK; Smith IE
    Br J Cancer; 2000 Jun; 82(12):1907-13. PubMed ID: 10864196
    [No Abstract]   [Full Text] [Related]  

  • 67. New oral chemotherapeutic agents for lung cancer.
    Bengtson EM; Rigas JR
    Drugs; 1999; 58 Suppl 3():57-69. PubMed ID: 10711843
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Breast cancer therapies in development. A review of their pharmacology and clinical potential.
    de Valeriola D; Awada A; Roy JA; Di Leo A; Biganzoli L; Piccart M
    Drugs; 1997 Sep; 54(3):385-413. PubMed ID: 9279502
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients.
    Schilling T; Fiebig HH; Kerpel-Fronius S; Winterhalter B; Variol P; Tresca P; Heinrich B; Hanauske AR
    Invest New Drugs; 1996; 14(4):371-8. PubMed ID: 9157072
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy of 5'-nor-anhydrovinblastine (vinorelbine), against freshly explanted clonogenic human tumor cells in vitro.
    Djuanda I; Depenbrock H; Peter R; Block T; Pohlmann G; Rastetter J; Hanauske AR
    Invest New Drugs; 1996; 14(2):153-9. PubMed ID: 8913836
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical pharmacokinetics of vinorelbine.
    Levêque D; Jehl F
    Clin Pharmacokinet; 1996 Sep; 31(3):184-97. PubMed ID: 8877249
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography.
    van Tellingen O; Kuijpers AV; Beijnen JH; Nooijen WJ; Bult A
    Invest New Drugs; 1993; 11(2-3):141-50. PubMed ID: 8262726
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pulmonary distribution of vinorelbine in patients with non-small-cell lung cancer.
    Levêque D; Quoix E; Dumont P; Massard G; Hentz JG; Charloux A; Jehl F
    Cancer Chemother Pharmacol; 1993; 33(2):176-8. PubMed ID: 8261579
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Biliary elimination and pharmacokinetics of vinorelbine in micropigs.
    Levêque D; Merle-Melet M; Bresler L; Didelot JP; Aymard JP; Wihlm J; Jehl F
    Cancer Chemother Pharmacol; 1993; 32(6):487-90. PubMed ID: 8258199
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy.
    Goa KL; Faulds D
    Drugs Aging; 1994 Sep; 5(3):200-34. PubMed ID: 7803948
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The current and future place of vinorelbine in cancer therapy.
    Cvitkovic E; Izzo J
    Drugs; 1992; 44 Suppl 4():36-45; discussion 66-9. PubMed ID: 1283849
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Preclinical and clinical pharmacology of vinca alkaloids.
    Zhou XJ; Rahmani R
    Drugs; 1992; 44 Suppl 4():1-16; discussion 66-9. PubMed ID: 1283846
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography.
    Jehl F; Quoix E; Leveque D; Pauli G; Breillout F; Krikorian A; Monteil H
    Cancer Res; 1991 Apr; 51(8):2073-6. PubMed ID: 1849042
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The clinical pharmacokinetics of vinorelbine (Navelbine).
    Wargin WA; Lucas VS
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):21-7. PubMed ID: 7973765
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin.
    Levêque D; Jehl F; Quoix E; Breillout F
    J Clin Pharmacol; 1992 Dec; 32(12):1096-8. PubMed ID: 1336784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.